GLENMARK PHARMACEUTICALS
|
The Current P/S Ratio of GLENMARK PHARMACEUTICALS is 3.64.
| Share Price | ₹2,122.2 | Mar 06,2026 |
| Market Cap | ₹59,887.1 Cr | |
| Sales-TTM | ₹16,468.1 Cr | TTM-Consolidated Results |
| Price/Sales | 3.64x | Calculated as Market Cap/Sales |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PS (Price/Sales) ratio of GLENMARK PHARMACEUTICALS
P/S =
Market Capitalization
/
Sales
or, using per-share numbers:
P/S = Stock Price / Sales Per Share
Current Market Cap [ ₹59,887.1 Cr] as on Mar 06,2026
(/) Sales [ ₹16,468.1 Cr] based on TTM-Consolidated Results
(=) P/S Ratio [ 3.64x ]
Thus, for GLENMARK PHARMACEUTICALS , the investors are currently willing to pay '3.64 times sales' to own 1 share of the company.
PS Multiples are one of the most widely used valuation multiple in the industry.
P/S ratios can be a reliable benchmark to compare companies with negative earnings or book value.
You may also explore Price to Earnings ratio or Price to Book ratio of GLENMARK PHARMACEUTICALS !
The chart below summarizes the trend in P/S Ratio of GLENMARK PHARMACEUTICALS over the last five years.
Historical PS (Price/Sales) ratio chart of GLENMARK PHARMACEUTICALS
PS Ratio Performance Analysis for GLENMARK PHARMACEUTICALS
- GLENMARK PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 1.78x.
- GLENMARK PHARMACEUTICALS 's operated at median p/e ratio of 1.2x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GLENMARK PHARMACEUTICALS 's p/e ratio peaked in Mar2025 at 3.26x.
- GLENMARK PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2022 of 1.01x.
How does GLENMARK PHARMACEUTICALS 's P/S Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Sales (Cr) | PS Ratio | Market Cap (Cr) |
|---|---|---|---|
| GLENMARK PHARMACEUTICALS | 16,468.1 | 3.64 | 59,887.1 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 56,809.1 | 7.60 | 431,628.0 |
| DIVIS LABORATORIES LTD | 10,314.0 | 16.29 | 167,975.0 |
| CIPLA LTD | 28,351.1 | 3.77 | 106,768.0 |
| TORRENT PHARMACEUTICALS LTD | 12,742.0 | 11.44 | 145,804.0 |
| DR REDDYS LABORATORIES LTD | 34,682.2 | 3.14 | 108,829.0 |
| MANKIND PHARMA LTD | 13,914.1 | 6.49 | 90,257.8 |
| ZYDUS LIFESCIENCES LTD | 26,089.3 | 3.52 | 91,864.1 |
| LUPIN LTD | 26,150.5 | 4.10 | 107,152.0 |
| AUROBINDO PHARMA LTD | 33,181.9 | 2.16 | 71,531.5 |
| ABBOTT INDIA LTD | 6,824.1 | 8.51 | 58,106.6 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PS Analysis vs GLENMARK PHARMACEUTICALS 's P/S Ratio
| Top 10 Industry Peers | PS Ratio |
|---|---|
| Min industry PS | 2.16x |
| Max industry PS | 16.29x |
| Median industry PS | 4.10x |
| Average industry PS | 6.42x |
You may also like the below Video Courses